ClinicalTrials.gg
Status unknownNCT03657758Updated Sep 18, 2018

Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]

A Phase 4 interventional study of EPA and rosuvastatin and High dose rosuvastatin in Coronary Artery Disease and Angina Pectoris, sponsored by Kobe University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-18.

Sponsored by Kobe University · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Planned enrollment
31st of 34
75 · median 175
Started
2018
the only one that year
Phase 4
22 of 34
none open now
Registered
28th of 34
by date
Lead sponsor
2 of 34
Kobe University

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 31st largest by planned enrollment, is the only one that started in 2018, is one of 22 in phase 4, and was the 28th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study aim is to evaluate the additional effect of eicosapentaenoic acid and dose up effect of rosuvastatin for neoatherosclerosis in coronary artery disease patients.

Read the detailed description

Eicosapentaenoic acid and statin therapy prevents cardiovascular events. However, the impact of these treatment in patients with in-stent neoatherosclerosis has not been clarified.

So, the investigators conducted LINK IT study. This study showed that eicosapentaenoic acid(EPA) and rosuvastatin therapy improve lipid index in patients compared with rosuvastatin alone therapy.

However, it was insufficient to directly evaluate the efficacy of additional effect of EPA for neoatherosclerosis. Because, statin dose of two groups was different and type of stent was variety.

Therefore, the investigators designed a new prospective, randomized OCT study. The OCT operators randomly assigned 75 patients who were detected neoatherosclerosis on follow-up OCT examination after implanted everolimus eluting stent to three groups; 5mg/day of rosuvastatin therapy (low dose statin therapy group) or 10mg/day of rosuvastatin therapy (high dose statin therapy group) or 10mg/day of rosuvastatin and 1800mg/day of eicosapentaenoic acid therapy (EPA and statin therapy group). Serial coronary angiography and OCT were performed at 9 months after baseline OCT procedure.

This study aim is to evaluate the additional effect of eicosapentaenoic acid and dose up effect of rosuvastatin for neoatherosclerosis in coronary artery disease patients by comparing 3 groups.

03

Conditions studied

  • Coronary Artery Disease
  • Angina Pectoris

Keywords

  • eicosapentaenoic acid
  • OCT
  • neoatherosclerosis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. over 20 years
  2. Patients implanted everolimus-eluting stent(EES) neoatherosccrelosis with neoatherosclerosis by OCT
  3. LDL is or less than 100 mg/dl after ingesting 5 mg/day of rosuvastatin

Exclusion criteria

Exclusion Criteria:

  1. Patients taking omega 3 fatty acid before randomization
  2. Patients allergic to rosuvastatin or eicosapentaenoic acid
  3. Patients with a history of hemorrhagic stroke
  4. Patients taking anti cancer agent
  5. Patients undergoing LDL apheresis
  6. Patients with severe liver disease or severe kidney disease
  7. Patients who conflict with any of the warnings or listed in the domestic package insert of rosuvastatin
  8. Patients who conflict with any of the warnings or contraindications listed in the domestic package insert of eicosapentaenoic acid
  9. Patients performed percutaneous coronary intervention with restenosis of target lesion
  10. Pregnant women or patients with possibility of Pregnancy or nursing woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Active comparator
    EPA and statin therapy group

    After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 9 months.

    Drug: EPA and rosuvastatin

  • Active comparator
    High dose statin therapy group

    After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for 9 months.

    Drug: High dose rosuvastatin

  • No intervention
    low dose statin therapy group

    After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for 9 months.

Interventions

06

What researchers measure

Primary outcomes

  1. The change in lipid index

    mean lipid arc ✕ lipid length

    Time frame: 9 months

Secondary outcomes

  1. MACE

    Major cerebro-cardiovascular events(Nonfatal stroke, Nonfatal myocardial infarction, cardiovascular death)

    Time frame: 9 months

  2. The change in minimum lumen area

    OCT parameter

    Time frame: 9 months

  3. The change in average neointimal thickness

    OCT parameter

    Time frame: 9 months

  4. The change in lipid arc

    OCT parameter

    Time frame: 9 months

  5. The change in lipid length

    OCT parameter

    Time frame: 9 months

  6. The change in thin cap fibroatheroma

    OCT parameter

    Time frame: 9 months

  7. The change in macrophage grade

    OCT parameter

    Time frame: 9 months

  8. The change in plaque volume

    Near infrared spectroscopy intravascular ultrasound(NIRS-IVUS) parameter

    Time frame: 9 months

  9. The change in max Lipid-core burden index

    NIRS-IVUS parameter

    Time frame: 9 months

07

Study locations

1 site
  • Kobe University Graduate School of Medicine, Department of Cardiology
    Kobe, Hyogo 650-0017, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2018; primary completion for Aug 2020, 23 months later.

Of 193 phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2018
First posted
Sep 5, 2018
StartEst.
Sep 17, 2018
Primary completionEst.
Aug 31, 2020
CompletionEst.
Aug 31, 2021
Last update
Sep 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03657758
Lead sponsor
Kobe University
Responsible party
Hiromasa Otake (Senior Lecturer, Kobe University) — Principal investigator
First posted
Sep 5, 2018
Start date
Sep 17, 2018 (estimated)
Primary completion
Aug 31, 2020 (estimated)
Completion
Aug 31, 2021 (estimated)
Last update
Sep 18, 2018

Study contacts

Hiromasa Otake, ph.D
Contact
hotake@med.kobe-u.ac.jp
+81-78-382-5846

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eicosapentaenoic Acid · Rosuvastatin

Start the discussion